Gaucher Disease (GD) - Market Insights, Epidemiology and Market Forecasts, 2024

Comments

Transcription

Gaucher Disease (GD) - Market Insights, Epidemiology and Market Forecasts, 2024
[email protected]
Gaucher Disease (GD) - Market Insights,
Epidemiology and Market Forecasts, 2024
The Report,” Gaucher Disease - Epidemiology Forecast to 2024" market research providing an overview
of the risk factors and global trends of GD in the 7MM US, France, Germany, Italy, Spain, UK, and Israel.
It includes a 10-year epidemiology forecast for the total prevalent cases of Type 1, 2, and 3 GD,
segmented by age and sex in these markets. GD epidemiology report is written and developed by
Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and
market-driven, providing expert analysis of disease trends in the 7MM.
The Report on Gaucher Disease is in-depth, high quality, transparent and market-driven, providing expert
analysis of disease trends in the 7MM.
Browse detailed TOC, Tables, figures, Charts and Companies mentioned in Gaucher Disease –
Epidemiology Forecast Report at- http://www.marketreportsworld.com/epicast-report-gaucher-diseaseepidemiology-forecast-to-2024-10077055
Epidemiologists forecast that the total prevalent cases of Type 1 GD in the 7MM will increase from 12,036
cases in 2014 to 13,006 cases in 2024, with the majority of cases occurring in the US and Israel. Types 2
and 3 GD are even more rare than Type 1, with only 121 cases of Type 2 and 613 cases of Type 3
across the 7MM in 2014. Epidemiologists predict that the total prevalent cases of Type 2 GD in the 7MM
will increase from 121 cases in 2014 to 125 cases in 2024, and that the total prevalent cases of Type 3
GD in the 7MM will increase from 613 cases in 2014 to 640 cases in 2024. The disease affects men and
women in equal numbers across the 7MM.
Request sample PDF of this report at- http://www.marketreportsworld.com/enquiry/requestsample/10077055
Gaucher Disease (GD) is a rare, inherited lysosomal storage disorder (LSD) that is classified into three
forms - Types 1, 2, and 3 - which are distinguished by their symptoms, severity, and neurological
involvement. GD affects the ability of cells to break down a specific type of fat, glucocerebroside (GC), as
a result of the deficiency or limited activity of the enzyme glucocerebrosidase (GCase). This leads to the
harmful accumulation of GC, which is also known as glucosylceramide, in the lysosomes, most commonly
in the macrophages and monocytes, throughout the body. The most significant difference between the
three types of GD is whether or not there is neurological involvement.
About Market Reports World:
Market Reports World is the credible source for gaining the market research reports that will exponentially
accelerate your business. We are among the leading report resellers in the business world committed
towards optimizing your business. The reports we provide are based on a research that covers a
magnitude of factors such as technological evolution, economic shifts and a detailed study of market
segments.
+1 408 520 9750
www.marketreportsworld.com
[email protected]
[email protected]
Contact–
Mr. Ameya Pingaley
Market Reports World
+1-408 520 9750
Email – [email protected]
Website: www.marketreportsworld.com
+1 408 520 9750
www.marketreportsworld.com
[email protected]

Similar documents

Diagnosed Prevalent Cases of Fabry Disease in The 7MM Will Rise at an AGR of 7.71% By 2024

Diagnosed Prevalent Cases of Fabry Disease in The 7MM Will Rise at an AGR of 7.71% By 2024 The report,” Fabry Disease - Epidemiology Forecast to 2024 “provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex.

More information

Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024

Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024 The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4% according to a leading research and consulting firm. Of the 7MM, Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024, representing a CAGR of 19.7%.

More information

Recent Research: Respiratory Syncytial Virus Treatment Market Will Surpass $2.3 Billion by 2024

Recent Research: Respiratory Syncytial Virus Treatment Market Will Surpass $2.3 Billion by 2024 According to a leading research and consulting firm, The Global Respiratory Syncytial Virus (RSV) treatment market will expand to unprecedented levels over the next decade, rising from approximately $640 million in 2014 to over $2.3 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 29.9%.

More information